| Autor: |
Bittner S; Leibniz Institute for Immunotherapy, 93053 Regensburg, Germany.; Chair for Immunology, Universität Regensburg, 93053 Regensburg, Germany., Ruhland B; Leibniz Institute for Immunotherapy, 93053 Regensburg, Germany.; Chair for Immunology, Universität Regensburg, 93053 Regensburg, Germany., Hofmann V; Leibniz Institute for Immunotherapy, 93053 Regensburg, Germany.; Chair for Immunology, Universität Regensburg, 93053 Regensburg, Germany., Schmidleithner L; Leibniz Institute for Immunotherapy, 93053 Regensburg, Germany.; Chair for Immunology, Universität Regensburg, 93053 Regensburg, Germany., Schambeck K; Leibniz Institute for Immunotherapy, 93053 Regensburg, Germany.; Chair for Immunology, Universität Regensburg, 93053 Regensburg, Germany., Pant A; Leibniz Institute for Immunotherapy, 93053 Regensburg, Germany.; Chair for Immunology, Universität Regensburg, 93053 Regensburg, Germany., Stüve P; Leibniz Institute for Immunotherapy, 93053 Regensburg, Germany.; Chair for Immunology, Universität Regensburg, 93053 Regensburg, Germany., Delacher M; Institute of Immunology, Universitätsmedizin Mainz, 55131 Mainz, Germany., Echtenacher B; Leibniz Institute for Immunotherapy, 93053 Regensburg, Germany.; Chair for Immunology, Universität Regensburg, 93053 Regensburg, Germany., Edinger M; Leibniz Institute for Immunotherapy, 93053 Regensburg, Germany.; Department of Internal Medicine III, Universitätsklinikum Regensburg, 93053 Regensburg, Germany., Hoffmann P; Leibniz Institute for Immunotherapy, 93053 Regensburg, Germany.; Department of Internal Medicine III, Universitätsklinikum Regensburg, 93053 Regensburg, Germany., Rehli M; Leibniz Institute for Immunotherapy, 93053 Regensburg, Germany.; Department of Internal Medicine III, Universitätsklinikum Regensburg, 93053 Regensburg, Germany., Gebhard C; Leibniz Institute for Immunotherapy, 93053 Regensburg, Germany., Strieder N; Leibniz Institute for Immunotherapy, 93053 Regensburg, Germany., Hehlgans T; Leibniz Institute for Immunotherapy, 93053 Regensburg, Germany.; Chair for Immunology, Universität Regensburg, 93053 Regensburg, Germany., Feuerer M; Leibniz Institute for Immunotherapy, 93053 Regensburg, Germany.; Chair for Immunology, Universität Regensburg, 93053 Regensburg, Germany. |
| Abstrakt: |
Engineered regulatory T cell (Treg cell) therapy is a promising strategy to treat patients suffering from inflammatory diseases, autoimmunity, and transplant rejection. However, in many cases, disease-related antigens that can be targeted by Treg cells are not available. In this study, we introduce a class of synthetic biosensors, named artificial immune receptors (AIRs), for murine and human Treg cells. AIRs consist of three domains: (a) extracellular binding domain of a tumor necrosis factor (TNF)-receptor superfamily member, (b) intracellular costimulatory signaling domain of CD28, and (c) T cell receptor signaling domain of CD3-ζ chain. These AIR receptors equip Treg cells with an inflammation-sensing machinery and translate this environmental information into a CD3-ζ chain-dependent TCR-activation program. Different AIRs were generated, recognizing the inflammatory ligands of the TNF-receptor superfamily, including LIGHT, TNFα, and TNF-like ligand 1A (TL1A), leading to activation, differentiation, and proliferation of AIR-Treg cells. In a graft-versus-host disease model, Treg cells expressing lymphotoxin β receptor-AIR, which can be activated by the ligand LIGHT, protect significantly better than control Treg cells. Expression and signaling of the corresponding human AIR in human Treg cells prove that this concept can be translated. Engineering Treg cells that target inflammatory ligands leading to TCR signaling and activation might be used as a Treg cell-based therapy approach for a broad range of inflammation-driven diseases. |
